Header Logo

Connection

Kathleen Moore to Humans

Back to Details
This is a "connection" page, showing publications Kathleen Moore has written about Humans.
Kathleen Moore
Connection Strength
1.763
Humans
  1. Physician-reported patient involvement and treatment decisions in first-line ovarian cancer in the USA and Europe. Int J Gynecol Cancer. 2024 Nov; 34(11):1753-1760.
    View in: PubMed
    Score: 0.054
  2. Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha-expressing recurrent ovarian cancer: An integrated safety summary. Gynecol Oncol. 2024 Dec; 191:249-258.
    View in: PubMed
    Score: 0.053
  3. Homologous recombination deficiency testing in first-line ovarian cancer. Ann Oncol. 2022 03; 33(3):231-233.
    View in: PubMed
    Score: 0.044
  4. Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study. Clin Cancer Res. 2022 01 01; 28(1):36-44.
    View in: PubMed
    Score: 0.043
  5. An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer. Gynecol Oncol. 2021 12; 163(3):473-480.
    View in: PubMed
    Score: 0.043
  6. A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic Cancer. Target Oncol. 2021 09; 16(5):569-589.
    View in: PubMed
    Score: 0.043
  7. PARP inhibitor associated treatment related myeloid neoplasms: What was a "Rare" complication may be less so. Gynecol Oncol. 2021 06; 161(3):639-641.
    View in: PubMed
    Score: 0.042
  8. Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. Ann Oncol. 2021 06; 32(6):757-765.
    View in: PubMed
    Score: 0.041
  9. Cost-effectiveness of olaparib as a maintenance treatment for women with newly diagnosed advanced ovarian cancer and BRCA1/2 mutations in the United States. Gynecol Oncol. 2020 11; 159(2):491-497.
    View in: PubMed
    Score: 0.040
  10. Niraparib in the treatment of previously treated advanced ovarian, fallopian tube or primary peritoneal cancer. Future Oncol. 2020 Nov; 16(33):2701-2711.
    View in: PubMed
    Score: 0.040
  11. A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53-mutant Ovarian Cancer. Clin Cancer Res. 2020 09 15; 26(18):4767-4776.
    View in: PubMed
    Score: 0.039
  12. Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer. Gynecol Oncol. 2020 09; 158(3):631-639.
    View in: PubMed
    Score: 0.039
  13. Tamrintamab pamozirine (SC-003) in patients with platinum-resistant/refractory ovarian cancer: Findings of a phase 1 study. Gynecol Oncol. 2020 09; 158(3):640-645.
    View in: PubMed
    Score: 0.039
  14. A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer. Gynecol Oncol. 2020 01; 156(1):13-22.
    View in: PubMed
    Score: 0.038
  15. A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer. Gynecol Oncol. 2019 08; 154(2):294-301.
    View in: PubMed
    Score: 0.037
  16. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019 05; 20(5):636-648.
    View in: PubMed
    Score: 0.036
  17. Angiopoietin-1 and Angiopoietin-2 Inhibitors: Clinical Development. Curr Oncol Rep. 2019 02 26; 21(3):22.
    View in: PubMed
    Score: 0.036
  18. Effect of niraparib on cardiac repolarization in patients with platinum-sensitive, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer. Cancer Chemother Pharmacol. 2019 04; 83(4):717-726.
    View in: PubMed
    Score: 0.036
  19. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2018 12 27; 379(26):2495-2505.
    View in: PubMed
    Score: 0.035
  20. Incidence of secondary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with ovarian or breast cancer in a real-world setting in the United States. Gynecol Oncol. 2018 11; 151(2):190-195.
    View in: PubMed
    Score: 0.035
  21. Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer. Gynecol Oncol. 2018 10; 151(1):46-52.
    View in: PubMed
    Score: 0.035
  22. Administration of the Tablet Formulation of Olaparib in Patients with Ovarian Cancer: Practical Guidance and Expectations. Oncologist. 2018 06; 23(6):697-703.
    View in: PubMed
    Score: 0.034
  23. The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities. Gynecol Oncol. 2018 04; 149(1):214-220.
    View in: PubMed
    Score: 0.033
  24. The effect of food on the pharmacokinetics of niraparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent ovarian cancer. Cancer Chemother Pharmacol. 2018 03; 81(3):497-503.
    View in: PubMed
    Score: 0.033
  25. Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 11; 147(2):396-401.
    View in: PubMed
    Score: 0.033
  26. Contribution of age to clinical trial enrollment and tolerance with ovarian cancer. Gynecol Oncol. 2017 04; 145(1):32-36.
    View in: PubMed
    Score: 0.031
  27. Endometrial Cancer: Is This a New Disease? Am Soc Clin Oncol Educ Book. 2017; 37:435-442.
    View in: PubMed
    Score: 0.031
  28. Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data analysis. Gynecol Oncol. 2016 Nov; 143(2):294-301.
    View in: PubMed
    Score: 0.030
  29. Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer. Oncologist. 2016 08; 21(8):954-63.
    View in: PubMed
    Score: 0.030
  30. Society of Gynecologic Oncology 2016 Annual Meeting: Highlights and context. Gynecol Oncol. 2016 06; 141(3):416-420.
    View in: PubMed
    Score: 0.030
  31. Is the NCI MATCH trial a match for gynecologic oncology? Gynecol Oncol. 2016 Jan; 140(1):161-6.
    View in: PubMed
    Score: 0.029
  32. A phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1/2 neutralizing peptibody, in patients with persistent/recurrent carcinoma of the endometrium: An NRG/Gynecologic Oncology Group trial. Gynecol Oncol. 2015 Sep; 138(3):513-8.
    View in: PubMed
    Score: 0.028
  33. Treatment Advances in Locoregionally Advanced and Stage IVB/Recurrent Cervical Cancer: Can We Agree That More Is Not Always Better? J Clin Oncol. 2015 Jul 01; 33(19):2125-8.
    View in: PubMed
    Score: 0.028
  34. Research: An event or an environment? Gynecol Oncol. 2014 Sep; 134(3):441-2.
    View in: PubMed
    Score: 0.026
  35. A Phase I cardiac safety and pharmacokinetic study of tivozanib hydrochloride in patients with advanced solid tumors. Clin Pharmacol Drug Dev. 2014 07; 3(4):284-9.
    View in: PubMed
    Score: 0.026
  36. Outcomes of cervical cancer and positive para-aortic lymph nodes in the modern era of chemoradiation. Int J Gynecol Cancer. 2014 Mar; 24(3):564-9.
    View in: PubMed
    Score: 0.025
  37. A phase I trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: A gynecologic oncology group study. Gynecol Oncol. 2012 Dec; 127(3):456-61.
    View in: PubMed
    Score: 0.023
  38. Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer?: a Gynecologic Oncology Group ancillary data analysis. Cancer. 2010 Dec 01; 116(23):5407-14.
    View in: PubMed
    Score: 0.020
  39. Adjuvant chemotherapy for the "oldest old" ovarian cancer patients: can we anticipate toxicity-related treatment failure in a vulnerable population? Cancer. 2009 Apr 01; 115(7):1472-80.
    View in: PubMed
    Score: 0.018
  40. Ovarian cancer in the octogenarian: does the paradigm of aggressive cytoreductive surgery and chemotherapy still apply? Gynecol Oncol. 2008 Aug; 110(2):133-9.
    View in: PubMed
    Score: 0.017
  41. Cervical dysplasia among women over 35 years of age. Am J Obstet Gynecol. 2008 Nov; 199(5):471.e1-5.
    View in: PubMed
    Score: 0.017
  42. Extraperitoneal para-aortic lymph node evaluation for cervical cancer via pfannenstiel incision: technique and peri-operative outcomes. Gynecol Oncol. 2008 Mar; 108(3):466-71.
    View in: PubMed
    Score: 0.017
  43. Serous fallopian tube carcinoma: a retrospective, multi-institutional case-control comparison to serous adenocarcinoma of the ovary. Gynecol Oncol. 2007 Dec; 107(3):398-403.
    View in: PubMed
    Score: 0.016
  44. Adolescent cervical dysplasia: histologic evaluation, treatment, and outcomes. Am J Obstet Gynecol. 2007 Aug; 197(2):141.e1-6.
    View in: PubMed
    Score: 0.016
  45. Pathologic findings and outcomes for octogenarians presenting with uterine malignancy. Gynecol Oncol. 2007 Sep; 106(3):572-8.
    View in: PubMed
    Score: 0.016
  46. Vesicovaginal fistula formation in patients with Stage IVA cervical carcinoma. Gynecol Oncol. 2007 Sep; 106(3):498-501.
    View in: PubMed
    Score: 0.016
  47. A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer. Gynecol Oncol. 2007 May; 105(2):299-303.
    View in: PubMed
    Score: 0.016
  48. Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup. Lancet Oncol. 2022 08; 23(8):e374-e384.
    View in: PubMed
    Score: 0.011
  49. Recent advances and clinical applications of deep learning in medical image analysis. Med Image Anal. 2022 07; 79:102444.
    View in: PubMed
    Score: 0.011
  50. Clinical analysis of pathologic complete responders in advanced-stage ovarian cancer. Gynecol Oncol. 2022 04; 165(1):82-89.
    View in: PubMed
    Score: 0.011
  51. Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion. J Clin Oncol. 2022 04 10; 40(11):1231-1258.
    View in: PubMed
    Score: 0.011
  52. Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer. Eur J Cancer. 2021 11; 157:415-423.
    View in: PubMed
    Score: 0.011
  53. Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial. Gynecol Oncol. 2021 10; 163(1):41-49.
    View in: PubMed
    Score: 0.011
  54. Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database. Lancet Haematol. 2021 Feb; 8(2):e122-e134.
    View in: PubMed
    Score: 0.010
  55. Developing a new radiomics-based CT image marker to detect lymph node metastasis among cervical cancer patients. Comput Methods Programs Biomed. 2020 Dec; 197:105759.
    View in: PubMed
    Score: 0.010
  56. PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer. Gynecol Oncol. 2020 11; 159(2):322-328.
    View in: PubMed
    Score: 0.010
  57. Anti-cancer therapy and clinical trial considerations for gynecologic oncology patients during the COVID-19 pandemic crisis. Gynecol Oncol. 2020 07; 158(1):16-24.
    View in: PubMed
    Score: 0.010
  58. Activity of M3814, an Oral DNA-PK Inhibitor, In Combination with Topoisomerase II Inhibitors in Ovarian Cancer Models. Sci Rep. 2019 12 11; 9(1):18882.
    View in: PubMed
    Score: 0.009
  59. Incorporation of whole pelvic radiation into treatment of stage IVB cervical cancer: A novel treatment strategy. Gynecol Oncol. 2020 01; 156(1):100-106.
    View in: PubMed
    Score: 0.009
  60. First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies. Clin Cancer Res. 2020 03 01; 26(5):1025-1033.
    View in: PubMed
    Score: 0.009
  61. Prediction of chemotherapy response in ovarian cancer patients using a new clustered quantitative image marker. Phys Med Biol. 2018 08 06; 63(15):155020.
    View in: PubMed
    Score: 0.009
  62. A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer. Gynecol Oncol. 2018 08; 150(2):274-281.
    View in: PubMed
    Score: 0.009
  63. Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma. Clin Cancer Res. 2018 07 15; 24(14):3263-3272.
    View in: PubMed
    Score: 0.008
  64. Anti-CD73 and anti-OX40 immunotherapy coupled with a novel biocompatible enzyme prodrug system for the treatment of recurrent, metastatic ovarian cancer. Cancer Lett. 2018 07 01; 425:174-182.
    View in: PubMed
    Score: 0.008
  65. Applying Quantitative CT Image Feature Analysis to Predict Response of Ovarian Cancer Patients to Chemotherapy. Acad Radiol. 2017 10; 24(10):1233-1239.
    View in: PubMed
    Score: 0.008
  66. MICU1 drives glycolysis and chemoresistance in ovarian cancer. Nat Commun. 2017 05 22; 8:14634.
    View in: PubMed
    Score: 0.008
  67. Multiplex profiling identifies distinct local and systemic alterations during intraperitoneal chemotherapy for ovarian cancer: An NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol. 2017 07; 146(1):137-145.
    View in: PubMed
    Score: 0.008
  68. A two-step convolutional neural network based computer-aided detection scheme for automatically segmenting adipose tissue volume depicting on CT images. Comput Methods Programs Biomed. 2017 Jun; 144:97-104.
    View in: PubMed
    Score: 0.008
  69. Applying a computer-aided scheme to detect a new radiographic image marker for prediction of chemotherapy outcome. BMC Med Imaging. 2016 08 31; 16(1):52.
    View in: PubMed
    Score: 0.008
  70. Utility of PET-CT to evaluate retroperitoneal lymph node metastasis in advanced cervical cancer: Results of ACRIN6671/GOG0233 trial. Gynecol Oncol. 2016 Sep; 142(3):413-9.
    View in: PubMed
    Score: 0.008
  71. Staging Lymphadenectomy in Patients With Clear Cell Carcinoma of the Ovary. Int J Gynecol Cancer. 2016 Jan; 26(1):120-4.
    View in: PubMed
    Score: 0.007
  72. Early prediction of clinical benefit of treating ovarian cancer using quantitative CT image feature analysis. Acta Radiol. 2016 Sep; 57(9):1149-55.
    View in: PubMed
    Score: 0.007
  73. Assessing the prognostic role of ATR mutation in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2015 Sep; 138(3):614-9.
    View in: PubMed
    Score: 0.007
  74. Chemotherapy Response Rates Among Patients With Endometrial Cancer Who Have Elevated Serum Platelets. Int J Gynecol Cancer. 2015 Jul; 25(6):1015-22.
    View in: PubMed
    Score: 0.007
  75. Patterns and utility of routine surveillance in high grade endometrial cancer. Gynecol Oncol. 2015 Jun; 137(3):485-9.
    View in: PubMed
    Score: 0.007
  76. A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumors. Invest New Drugs. 2014 Feb; 32(1):87-93.
    View in: PubMed
    Score: 0.006
  77. Patterns of recurrence in stage I endometrioid endometrial adenocarcinoma with lymphovascular space invasion. Int J Gynecol Cancer. 2013 Jan; 23(1):98-104.
    View in: PubMed
    Score: 0.006
  78. Stage I, grade 3 endometrioid adenocarcinoma of the endometrium: an analysis of clinical outcomes and patterns of recurrence. Gynecol Oncol. 2010 Jan; 116(1):10-4.
    View in: PubMed
    Score: 0.005
  79. A LEEP cervical conization is rarely indicated for a two-step discrepancy. J Low Genit Tract Dis. 2007 Jul; 11(3):134-7.
    View in: PubMed
    Score: 0.004
  80. The safety and efficacy of laparoscopic surgical staging of apparent stage I ovarian and fallopian tube cancers. Am J Obstet Gynecol. 2005 May; 192(5):1614-9.
    View in: PubMed
    Score: 0.003
  81. Total laparoscopic radical hysterectomy with pelvic lymphadenectomy using the argon-beam coagulator: pilot data and comparison to laparotomy. Gynecol Oncol. 2003 Nov; 91(2):402-9.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.